Phase II study of three-dimensional conformal radiotherapy and concurrent mitomycin-C, vinblastine, and cisplatin chemotherapy for Stage III locally advanced, unresectable, non-small-cell lung cancer

International Journal of Radiation Oncology Biology Physics

Volumn 56, Issue 4, 2003, Pages 996-1004

  Lee, Sang Wook ^a   Choi, Eun Kyung ^a,b   Lee, Jung Shin ^a   Lee, Sang Do ^a   Suh, Cheolwon ^a   Kim, Sang We ^a   Kim, Woo Sung ^a   Ahn, Seung Do ^a   Yi, Byong Yong ^a   Kim, Jong Hoon ^a   Noh, Young Ju ^a   Kim, Su Ssan ^a   Koh, Younsuck ^a   Kim, Dong Soon ^a   Kim, Won Dong ^a  

^a University of Ulsan College of Medicine   (South Korea)

^b University of Ulsan   (South Korea)

Author keywords

3D CRT; CCRT; NSCLC

Indexed keywords

CHEMOTHERAPY; PULMONARY DISEASES; RADIOTHERAPY; TOXICITY;

CONFORMAL RADIOTHERAPY;

TUMORS;

CISPLATIN; MITOMYCIN C; VINBLASTINE;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; ESOPHAGITIS; EVALUATION; FEMALE; FOLLOW UP; FRACTIONATION; HUMAN; LEUKOPENIA; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; NAUSEA; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; RADIATION DOSE; SURVIVAL RATE; TREATMENT OUTCOME; VOMITING; WEIGHT REDUCTION;

EID: 0037710405     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0360-3016(03)00127-5     Document Type: Article

References (32)

1. Dillman R.O., Seagren S.L., Propert K.L., et al. A randomized trial of induction chemotherapy plus high-dose radiation versus radiation alone in stage III non-small-cell lung cancer . N Engl J Med. 323:1990;940-945.
2. LeChevalier T., Arriagada R., Quoix E., et al. Radiotherapy alone versus combined chemotherapy and radiotherapy in nonresectable non-small cell lung cancer First analysis of a randomized trial in 353 patients . J Natl Cancer Inst. 83:1991;417-423.
3. Schaake-Koning C., van den Bogaert W., Dalesio O., et al. Effects of concomitant cisplatin and radiotherapy on inoperable non-small-cell lung cancer. N Engl J Med. 326:1992;524-530.
4. Bleehen N.M., Ball D., Belani C.P., et al. Combined radiation and chemotherapy for unresectable non-small cell lung carcinoma. Lung Cancer. 10:(Suppl. 1):1994;S19-S23. [Abstract].
5. Sause W.T., Scott C., Taylor S., et al. Radiation Therapy Oncology Group (RTOG 88-08) and Eastern Cooperative Oncology Group (ECOG) 4588 Preliminary results of a phase III trial in regionally advanced, unresectable, non-small cell lung cancer . J Natl Cancer Inst. 87:1995;198-205.
6. Sause W.T., Turrisi A.T. Principles and application of preoperative and standard radiotherapy for regionally advanced non small cell lung cancer. Pass H.I., Mitchell J.B., Johnson D.H. Lung cancer Principles and practice . 1996;697-710 Lippincott-Raven, Philadelphia.
7. Perez C.A., Stanley K., Grundy G., et al. Impact of irradiation technique and tumor extent in tumor control and survival of patients with unresectable non-oat cell carcinoma of the lung Report by the Radiation Therapy Oncology Group . Cancer. 50:1981;1091-1099.
8. Clinical practice guidelines for the treatment of unresectable non-small-cell lung cancer. Adopted on May 16, 1997 by American Society of Clinical Oncology. J Clin Oncol. 15:1997;2996-3001.
9. Wozniak A.J., Crowley J.J., Balcerzak S.P., et al. Randomized trial comparing cisplatin with cisplatin plus vinorelbine in the treatment of advanced non-small-cell lung cancer A Southwest Oncology Group study . J Clin Oncol. 16:1998;2459-2465.
10. Wozniak A.J., Crowley J.J., Balcerzak S.P., et al. Randomized phase III trial of cisplatin (CDDP) vs. CDDP plus Navelbine (NVB) in treatment of advanced non-small cell lung cancer (NSCLC) An update of a Southwest Oncology Group study (SWOG-9308) . Proc Am Soc Clin. 17:1998;453a.
11. Rosell R., Tonato M., Sandler A. The activity of gemcitabine plus cisplatin in randomized trials in untreated patients with advanced non-small cell lung cancer. J Clin Oncol. 17:1999;12-18.
12. Armstrong J., Burman C., Leibel S., et al. Conformal three dimensional treatment planning may improve the therapeutic ratio of high dose radiation therapy for lung cancer. Int J Radiat Oncol Biol Phys. 26:1993;685-689.
13. Emami B., Purdy J.A., Manolis J., et al. Three-dimensional treatment planning for lung cancer. Int J Radiat Oncol Biol Phys. 21:1991;217-227.
14. Leibel S., Kutcher J., Mohan R., et al. Three-dimensional conformal radiation therapy at the Memorial Sloan-Kettering Cancer Center. Semin Radiat Oncol. 2:1992;274-289.
15. Mountain C.F. A new international staging system for lung cancer. Chest. 89:(Suppl.):1986;225s-233s.
16. Kaplan E.L., Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 53:1958;457-481.
17. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep. 50:1966;163-170.
18. Lyman T.J. Complication probability as assessed from dose volume histograms. Radiat Res. 104:1985;S13-S19.
19. Kutcher G.J., Burman C. Calculation of complication probability factors for nonuniform normal tissue irradiation The effective volume method . Int J Radiat Oncol Biol Phys. 16:1989;1623-1630.
20. Choi E.K., Chang H.S., Ahn S.D., et al. Hyperfractionated radiotherapy following induction chemotherapy for stage III non-small cell lung cancer - Randomized for adjuvant chemotherapy vs. observation. J Korean Soc Ther Radiol. 11:1993;295-301.
21. Gralla R.J., Kris M.G. Chemotherapy in non-small cell lung Results of recent trials . Semin Oncol. 15:(Suppl. 4):1988;2.
22. Bonomi P. Brief overview of combination chemotherapy in non-small cell lung cancer. Semin Oncol. 13:1986;89-91.
23. Tejedor M., Valerdi J.J., Lopez R., et al. Mitomycin, cisplatin, and vindesine followed by radiotherapy combined with cisplatin in stage III nonsmall cell lung cancer Long-term results . Int J Radiat Oncol Biol Phys. 31:1995;813-818.
24. Smith I.E., O'Brien M.E.R., Talbot D.C., et al. Duration of chemotherapy in advanced non-small-cell lung cancer A randomized trial of three versus six course of mitomycin, vinblastine, and cisplatin . J Clin Oncol. 19:2001;1336-1343.
25. Byhardt R.W., Scott C., Sause W.T., et al. Response, toxicity, failure patterns, and survival in five Radiation Therapy Oncology Group (RTOG) trials of sequential and/or concurrent chemotherapy and radiotherapy for locally advanced non-small-cell carcinoma of the lung. Int J Radiat Oncol Biol Phys. 42:1998;469-478.
26. Cox J.D., Azarnia N., Byhardt R.W., et al. A randomized phase I/II trial of hyperfractionated radiation therapy with total doses 60.0 Gy to 79.2 Gy Possible survival benefit with ≥69.6 Gy in favorable patients with Radiation Therapy Oncology Group stage III nonsmall cell lung carcinoma - Report of Radiation Therapy Oncology Group 83-11 . J Clin Oncol. 8:1990;1543-1555.
27. Uitterhoeve A.L.J., Belderbos J.S.A., Koolen M.G.J., et al. Toxicity of high-dose radiotherapy combined with daily cisplatin in non-small cell lung cancer Results of the EORTC 08912 phase I/II study . Eur J Cancer. 8:1990;592-600.
28. Armstrong J., Raben A., Zelefsky M., et al. Promising survival with three-dimensional conformal radiation therapy for non-small cell lung cancer. Radiother Oncol. 44:1997;17-22.
29. Choi N.C.H., Doucette J.A. Improved survival of patients with unresectable non-small cell bronchogenic carcinoma by an innovated high-dose en bloc radiotherapeutic approach. Cancer. 48:1981;101-109.
30. Petrovich Z., Stanley K., Cox J., et al. Radiotherapy and the management of locally advanced lung cancer of all cell types Final report of randomised trial . Cancer. 48:1981;1335-1340.
31. Hayman J.A., Martel M.K., Ten Haken R.K., et al. Dose escalation in non-small-cell lung cancer using three-dimensional conformal radiation therapy Update of a phase I trial . J Clin Oncol. 19:2001;127-136.
32. Sibley G.S., Mundt A.J., Shapiro C., et al. The treatment of stage III nonsmall cell lung cancer using high dose conformal radiotherapy. Int J Radiat Oncol Biol Phys. 33:1995;1001-1007.